Get the Stockscreener App
16.64
13.97%
2.04
After Hours:
17.29
0.65
+3.91%
Arcus Biosciences Inc stock is traded at $16.64, with a volume of 1.87M.
It is up +13.97% in the last 24 hours and up +44.44% over the past month.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
See More
Previous Close:
$14.60
Open:
$15.8
24h Volume:
1.87M
Relative Volume:
2.22
Market Cap:
$1.77B
Revenue:
$247.00M
Net Income/Loss:
$-249.00M
P/E Ratio:
-5.3851
EPS:
-3.09
Net Cash Flow:
$-267.00M
1W Performance:
+14.92%
1M Performance:
+44.44%
6M Performance:
+103.42%
1Y Performance:
-9.42%
1-Day Range:
$15.09
$17.19
1-Week Range:
$13.71
$17.19
52-Week Range:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
16.64 | 1.55B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Citigroup Raises Price Target for RCUS to $54, Maintains Buy Rat - GuruFocus
Arcus Biosciences stock rises after strong gastric cancer survival data - Investing.com
Arcus Biosciences (RCUS) Shares Surge Following Positive Study R - GuruFocus
Arcus Biosciences rises on results from domvanalimab cancer study - Seeking Alpha
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga
Why Arcus Biosciences Inc. stock is rated strong buyEarnings Summary Report & AI Driven Stock Movement Reports - newser.com
What MACD signals say about Arcus Biosciences Inc.2025 Key Lessons & Weekly High Potential Stock Alerts - newser.com
Visual analytics tools that track Arcus Biosciences Inc. performancePortfolio Risk Report & Growth Focused Stock Pick Reports - newser.com
Applying sector rotation models to Arcus Biosciences Inc.July 2025 Sentiment & Expert Verified Movement Alerts - newser.com
Arcus Biosciences (RCUS) Reveals Promising Phase 2 Gastric Cance - GuruFocus
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ - Stocktwits
Arcus Biosciences to present promising gastric cancer survival data - Investing.com
Arcus Bioscience announces first overall survival results from phase 2 edge-gastric study - MarketScreener
Arcus Biosciences Shows 26.7‑Month Median OS in EDGE‑Gastric | RCUS Stock News - Stock Titan
Will Arcus Biosciences Inc. stock benefit from sector rotationJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
Price momentum metrics for Arcus Biosciences Inc. explainedWeekly Trend Summary & AI Driven Price Predictions - newser.com
Arcus Biosciences (NYSE:RCUS) COO Jennifer Jarrett Sells 37,792 Shares of Stock - MarketBeat
60,300 Options at $15.05 — Arcus Biosciences Grants 30,150 RSUs under 2020 Inducement Plan - Stock Titan
Arcus Biosciences Hits Day High with Strong 7.27% Intraday Surge - Markets Mojo
Arcus Biosciences Hits Day High with Strong 8.46% Intraday Surge - Markets Mojo
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data By Investing.com - Investing.com Australia
Arcus Biosciences COO Jarrett sells $750k in shares By Investing.com - Investing.com Canada
Arcus Biosciences’ SWOT analysis: oncology firm’s stock faces pivotal data - Investing.com India
Arcus Biosciences (RCUS) Soars 8.5%: Is Further Upside Left in the Stock? - MSN
Weiss Ratings Reaffirms "Sell (D-)" Rating for Arcus Biosciences (NYSE:RCUS) - MarketBeat
Cantor Fitzgerald reiterates Overweight rating on Arcus Biosciences stock By Investing.com - Investing.com Canada
RCUS: Truist Securities Raises Price Target for Arcus Biosciences | RCUS Stock News - GuruFocus
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment - inkl
A Fresh Look at Arcus Biosciences (RCUS) Valuation After New Casdatifan Data and Expanded Pipeline Initiatives - Yahoo Finance
Arcus Biosciences announces new anti-inflammation programs - BioWorld MedTech
Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating - MarketScreener
Arcus Biosciences Presents Promising ARC-20 Study Data - MSN
Why Is Arcus Biosciences Stock Trading Higher On Monday? - Sahm
Arcus Biosciences (NYSE:RCUS) Trading Up 15.2%Here's What Happened - MarketBeat
Transcript : Arcus Biosciences, Inc.Shareholder/Analyst Call - MarketScreener
Arcus Biosciences (RCUS) Sees Promising Results in Latest Study - GuruFocus
Arcus Biosciences (RCUS) Shares Positive Data on Casdatifan for Metastatic RCC - GuruFocus
Arcus Biosciences presents new data for its HIF-2a inhibitor casdatifan - MarketScreener
Arcus Biosciences reports positive casdatifan data, expands into inflammation - StreetInsider
Can momentum traders help lift Arcus Biosciences Inc.Weekly Stock Recap & Weekly High Return Forecasts - newser.com
What drives Arcus Biosciences Inc stock priceSector Performance Drivers & Free Superior Stock Performance - earlytimes.in
How to use Fibonacci retracement on Arcus Biosciences Inc.Trade Analysis Summary & Safe Capital Allocation Plans - newser.com
Published on: 2025-10-05 02:17:26 - newser.com
Pleasing Signs As A Number Of Insiders Buy Arcus Biosciences Stock - simplywall.st
Technical analysis overview for Arcus Biosciences Inc. stockJuly 2025 Catalysts & Weekly Momentum Picks - newser.com
Arcus Biosciences, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators - Markets Mojo
Arcus Biosciences Hits Day High with 9.94% Surge in Strong Intraday Performance - Markets Mojo
Barclays Keeps Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,831 Shares - MarketBeat
Published on: 2025-09-30 20:31:22 - newser.com
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arcus Biosciences Inc Stock (RCUS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | Chief Operating Officer |
Oct 06 '25 |
Option Exercise |
1.23 |
12,500 |
15,345 |
226,732 |
| Jarrett Jennifer | Chief Operating Officer |
Oct 08 '25 |
Sale |
15.05 |
37,792 |
568,611 |
214,232 |
| Jarrett Jennifer | Chief Operating Officer |
Oct 06 '25 |
Sale |
14.54 |
12,500 |
181,801 |
214,232 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):